Cargando…

Erratum to “Durable Objective Response to Sorafenib and Role of Sequential Treatment in Unresectable Hepatocellular Carcinoma”

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289899/ https://www.ncbi.nlm.nih.gov/pubmed/35860834 http://dx.doi.org/10.1177/17588359221112982

Ejemplares similares

Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma
por: Huang, Kuo-Wei, et al.
Publicado: (2022)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma
por: Wang, Hung-Wei, et al.
Publicado: (2021)

Erratum to miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1
Publicado: (2022)

Erratum to: Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index
por: Ohki, Takamasa, et al.
Publicado: (2017)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
por: Ko, Yi-Ling, et al.
Publicado: (2020)

Erratum to: Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis
por: Ohki, Takamasa, et al.
Publicado: (2016)

Erratum to: Sorafenib-Associated Facial Acneiform Eruption
por: Cohen, Philip R.
Publicado: (2015)

Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma
por: Takano, Michitoshi, et al.
Publicado: (2016)

Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
por: Ni, Hong, et al.
Publicado: (2011)

Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
por: Marconato, Laura, et al.
Publicado: (2020)

Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting
por: Fukushima, Taito, et al.
Publicado: (2021)

Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response
por: Zhang, Yingqiang, et al.
Publicado: (2015)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
por: Leung, Henry W. C., et al.
Publicado: (2016)

Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure
por: Li, Xiaomi, et al.
Publicado: (2022)

Erratum for Juvenile Hepatocellular Carcinoma in a Healthy Liver
por: Onishi, Sachiyo, et al.
Publicado: (2022)

Erratum: Management of Hepatocellular Carcinoma: Current Status and Future Directions
Publicado: (2015)

Erratum: Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma
por: Zhao, Ling-Hao, et al.
Publicado: (2016)

Uncompromised Treatment Efficacy in Elderly Patients With Hepatocellular Carcinoma: A Propensity Score Analysis: Erratum
Publicado: (2015)

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
por: Mahvash, Armeen, et al.
Publicado: (2016)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Erratum to: Understanding of and reasoning about object–object relationships in long‐tailed macaques?
por: Schloegl, Christian, et al.
Publicado: (2013)

Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study [Expression of concern] [Erratum]
Publicado: (2020)

Erratum to the genetic association between type 2 diabetic and hepatocellular carcinomas
Publicado: (2022)

Erratum to atractylodin may induce ferroptosis of human hepatocellular carcinoma cells
Publicado: (2023)

Erratum: Objective and Subjective Working Hours and Their Roles on Workers’ Health among Japanese Employees
por: OCHIAI, Yuko, et al.
Publicado: (2020)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
por: Wang, Wan, et al.
Publicado: (2019)

Erratum to: Sequential treatment for a patient with hemifacial microsomia: 10 year-long term follow up
por: Seo, Jeong-Seok, et al.
Publicado: (2015)

Effect of CELSR3 on the Cell Cycle and Apoptosis of Hepatocellular Carcinoma Cells: Erratum
por: Xie, Zucheng, et al.
Publicado: (2022)

Erratum to: Factors predicting survival after post-transplant hepatocellular carcinoma recurrence
por: Toso, Christian, et al.
Publicado: (2013)

Erratum to: Regulation of the hypoxic tumor environment in hepatocellular carcinoma using RNA interference
por: Choi, Sung Hoon, et al.
Publicado: (2017)

Erratum to: Hepatocellular carcinoma with extrahepatic blood supply from right renal artery
por: Sohail, Amir Humza, et al.
Publicado: (2021)

Hepatocellular Carcinoma Patients With Performance Status 1 Deserve New Classification and Treatment Algorithm in the BCLC System: Erratum
Publicado: (2015)

The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China
por: Meng, Rui, et al.
Publicado: (2022)

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
por: Su, Dan, et al.
Publicado: (2021)

Meta-analysis of possible role of cadherin gene methylation in evolution and prognosis of hepatocellular carcinoma with a PRISMA guideline: Erratum
Publicado: (2017)

Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma
por: Lee, I-Cheng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fst69rvongt0q9rhnpo0e49r9q